Literature DB >> 19050068

Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab.

Rohit Sud, Jonathan W Friedberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19050068      PMCID： PMC2898124          DOI： 10.3324/haematol.2008.000984

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

2.  Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project.

Authors:  J R Anderson; J O Armitage; D D Weisenburger
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

3.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

4.  Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

Authors:  Issa F Khouri; Rima M Saliba; Chitra Hosing; Grace-Julia Okoroji; Sandra Acholonu; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Michele L Donato; Luis Fayad; Segio Giralt; Roy Jones; Martin Korbling; Farzaneh Maadani; John T Manning; Barbara Pro; Elizabeth Shpall; Anas Younes; Peter McLaughlin; Richard E Champlin
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.

Authors:  C Soussain; B Souleau; J Gabarre; H Zouabi; L Sutton; C Boccaccio; N Albin; F Charlotte; H Merle-Béral; J Delort; J L Binet; V Leblond
Journal:  Leuk Lymphoma       Date:  1999-05

Review 6.  Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.

Authors:  Peter Martin; Richard R Furman; Jia Ruan; Rebecca Elstrom; Jacqueline Barrientos; Ruben Niesvizky; Morton Coleman; John P Leonard
Journal:  Semin Hematol       Date:  2008-04       Impact factor: 3.851

7.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

Authors:  O W Press; J F Eary; F R Appelbaum; P J Martin; C C Badger; W B Nelp; S Glenn; G Butchko; D Fisher; B Porter
Journal:  N Engl J Med       Date:  1993-10-21       Impact factor: 91.245

8.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

Authors:  Tarun Kewalramani; Andrew D Zelenetz; Stephen D Nimer; Carol Portlock; David Straus; Ariela Noy; Owen O'Connor; Daniel A Filippa; Julie Teruya-Feldstein; Alison Gencarelli; Jing Qin; Alyson Waxman; Joachim Yahalom; Craig H Moskowitz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

9.  SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

Authors:  Linfeng Chen; Stefano Monti; Przemyslaw Juszczynski; John Daley; Wen Chen; Thomas E Witzig; Thomas M Habermann; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

10.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Steven M Horwitz; Robert S Negrin; Karl G Blume; Sheila Breslin; Monic J Stuart; Keith E Stockerl-Goldstein; Laura J Johnston; Ruby M Wong; Judith A Shizuru; Sandra J Horning
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113
View more
  8 in total

Review 1.  Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis.

Authors:  Teruhiko Terasawa; Issa J Dahabreh; Takashi Nihashi
Journal:  Oncologist       Date:  2010-06-29

2.  R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.

Authors:  Alejandro Martín; María-Dolores Caballero
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

3.  Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas.

Authors:  Paolo G Gobbi; Lara Villano; Donatella Pozzoli; Manuela Bergonzi
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

4.  MicroRNAs in diffuse large B-cell lymphoma.

Authors:  Huiyun Ni; Rong Tong; Linqing Zou; Guoqi Song; William C Cho
Journal:  Oncol Lett       Date:  2015-12-28       Impact factor: 2.967

5.  Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.

Authors:  Lamiss Mohamed Abd el Aziz
Journal:  Med Oncol       Date:  2014-10-08       Impact factor: 3.064

6.  Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.

Authors:  Umar Farooq; Matthew J Maurer; Carrie A Thompson; Gita Thanarajasingam; David J Inwards; Ivana Micallef; William Macon; Sergei Syrbu; Tasha Lin; Yi Lin; Stephen M Ansell; Grzegorz S Nowakowski; Thomas M Habermann; James R Cerhan; Brian K Link
Journal:  Br J Haematol       Date:  2017-06-27       Impact factor: 6.998

7.  The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.

Authors:  Ting-Xun Lu; Yi Miao; Jia-Zhu Wu; Qi-Xing Gong; Jin-Hua Liang; Zhen Wang; Li Wang; Lei Fan; Dong Hua; Yao-Yu Chen; Wei Xu; Zhi-Hong Zhang; Jian-Yong Li
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

Review 8.  Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

Authors:  Amit Dipak Amin; Tara L Peters; Lingxiao Li; Soumya Sundara Rajan; Ramesh Choudhari; Soham D Puvvada; Jonathan H Schatz
Journal:  Cold Spring Harb Mol Case Stud       Date:  2017-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.